baber/WOPTO huggingface dataset:
Patent NZ-531515-A (NZ)
Title: Methods for the identification of polypeptide antigens associated with disorders involving aberrant cell proliferation and compositions useful for the treatment of such disorders
Inventor: LEVINSON ARTHUR D
IPC: G01N33/53
Filed: 2002-09-04
Abstract: Methods and compositions for the development of effective cancer therapies using mitotic inhibitors which have limited general toxicity to normal, non-cancerous cells and tissues are provided. The methods and compositions utilise cytotoxic compounds comprised of a cell-binding agent (e.g., antibodies) conjugated to an anti-mitotic compound (e.g., maytansinoids). Also provided are antibodies that are substantially incapable of inducing antibody-dependent cell-mediated cytotoxicity (ADCC) and/or complement dependent cytotoxicity (CDC), thereby ensuring the therapeutic effect is mediated primarily by the anti-mitotic component of the cytotoxic compound, rather than by indirect cell killing via ADCC and/or CDC. The antibodies are capable of differentiating between polypeptide antigens, which are more highly expressed on proliferating cancer cells as compared with proliferating non-cancer cells.
Patent NZ-534333-A (NZ)
Title: Pharmaceutical composition comprising N-[(1-n-butyl-4-piperidinyl) methyl]-3,4-dihydro-2H-[1, 3]oxazino[3, 2-a]indole-10-carboxamide or salt, and process for preparing thereof comprising dry granulation
Inventor: BUXTON PHILIP CHRISTOPHER
IPC: A61K31/535
Filed: 2003-01-22
Abstract: A process for preparing a pharmaceutical composition comprising N-[(1-nbutyl-4-piperidinyl) methyl]-3, 4-dihydro-2H-[1, 3]oxazino[3, 2-a]indole-10-carboxamide (SB 207266) in combination with one or more pharmaceutically acceptable excipients. The process comprising forming part or all of the SB 207266 into granules by a dry granulation process. Wherein the SB 207266 is present in the composition in at least 4 % by weight of the composition.
Patent NZ-535211-A (NZ)
Title: Dispensing apparatus with coding means
Inventor: CROSSDALE GARRY WILLIAM
IPC: B67D3/00
Filed: 2003-03-04
Abstract: A dispensing apparatus for delivering fluid or liquid to a container (1), e.g. a bottle, has a container holding means (2, 2') including mechanical keying means to permit a container with a predetermined identifier key to be completely inserted to a refill position in the container. Fluid delivery means (29, 32, 33) delivering fluid to a dispensing outlet (18), under control of an actuation member (20) which causes the fluid delivery means to deliver fluid in response to movement of the actuation member from its start position. A dispensing lock (9, 9', 16) has a first position in which it engages a portion of the actuation member to prevent movement of the actuation member from its start position, and a second position in which it permits movement of the actuation member. Release means (3, 4, 5, 7) for releasing the dispensing lock includes a movable release member (3) which is moved by the container, during its insertion into the refill position, so as to release the dispensing lock by bringing the dispensing lock to said second position, thus enabling fluid to be delivered.
Patent NZ-536070-A (NZ)
Title: Shoes with side panel for connection outsole
Inventor: MING-TE CHEN
Filed: 2004-10-21
Abstract: A shoe (1) includes a vamp (10) with an insole (4) and a side panel (2) encloses a periphery of a lower portion of the vamp. The side panel includes a plurality of apertures (20) and at least one gap (21) is defined between the vamp (10) and the side panel (2). Material such as rubber for an outsole encloses the side panel and is filled in the at least one gap and the apertures. The shoe needs no stitching and gluing.
Patent NZ-549805-A (NZ)
Title: A roading system
Inventor: CROSSLAND STEVEN GEORGE
Filed: 2006-09-08
Abstract: A roading system comprises a base element of packed particulate material. The base element includes a first bedding and/or filtration layer having a particulate material size of less than 6mm, a second drainage layer having a particulate material size of less than 14mm and a third structural layer having a particulate material size of less than 42mm.
Patent NZ-554838-A (NZ)
Title: Improved parasiticide paste
Inventor: LAU KAI KIN
Filed: 2007-05-01
Abstract: Disclosed is a stable oral paste formulation for treating parasites comprising: a) about 10-35% w/w praziquantel; b) about 0.5-50% w/w of one or more macrocyclic lactones; c) about 1-8% w/w of one or more solubilising agents for solubilising the one or more macrocyclic lactones; d) about 1-10% w/w of one or more surfactants; e) about 10-50% w/w of one or more saccharides; and f) optionally about 2-15% w/w of one or more humectants, and its use in controlling and/or treating an infestation of parasites in a non-human animal.
Patent NZ-566660-A (NZ)
Title: Aryl-substituted nitrogen-containing heterocyclic compound
Inventor: OKAMOTO OSAMU
IPC: A61K31/402
Filed: 2006-09-28
Abstract: Disclosed is an aryl-substituted nitrogen-containing heterocyclic compound represented by the formula (I) wherein the substituents are defined in the specification or a pharmaceutically acceptable salt thereof. This compound serves as a nociceptin receptor antagonist and is useful as a pharmaceutical agent for treating diseases associated with a nociceptin receptor.
Patent NZ-571343-A (NZ)
Title: 6,7,8,9-Tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl-amine derivatives as modulators of TRPV1 for the treatment of pain
Inventor: ALLISON BRETT D
IPC: A61P25/04
Filed: 2007-03-21
Abstract: Disclosed are 6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-yl-amine derivatives as represented by the general formula (I), wherein: Ar is a phenyl, pyridyl, imidazolyl, pyrimidinyl, pyridazinyl, or a fused-bicyclic heteroaryl group, each of which may be unsubstituted or substituted with one, two, or three Rk substituents; R2 is -H or alkyl; R3 is a monocyclic cycloalkyl, phenyl, benzyl, phenethyl, indanyl, thiazolyl, thiophenyl, pyridyl, pyridylmethyl, pyrimidinyl, pyrazinyl, pyridazinyl, benzothiadiazolyl, quinolinyl, isoquinolinyl, tetrahydroquinolinyl, or tetrahydroisoquinolinyl group each of which may be unsubstituted or substituted with one, two, or three R9 substituents; and wherein the remaining substituents are as defined herein. Further disclosed is a pharmaceutical composition which comprises a compound as defined above for use in treating conditions which are mediated by TRPV1 activity, and particularly for the treatment of conditions such as pain, itch, coughing, asthma or inflammatory bowel disease.
Patent NZ-574547-A (NZ)
Title: Hair styling agents giving a high degree of hold
Inventor: KNAPPE THORSTEN
IPC: A61K8/81
Filed: 2007-08-16
Abstract: An agent that can temporarily shape keratin fibres or hair. The agent comprises: a) a film-forming and/or setting amphoteric polymer A selected from the group of (i) methacryloyl-betaine/alkyl methacrylate copolymers, (ii) copolymers of monomers with carboxyl groups and/or sulfonic acid groups and monomers with amino groups, and (iii) copolymers of N-octylacrylic acid amide, methyl methacrylate, hydroxypropyl methacrylate, N-tert-butylaminoethyl methacrylate and acrylic acid; and b) a copolymer B made up from - one monomer B1 selected from acrylic acid amide, methacrylic acid amide, N-alkylacrylic acid amide and N-alkyl-methacrylic acid amide, - one monomer B2 selected from N-vinyllactams, - one monomer B3 selected from quaternized N-vinylimidazoles - the monomer N-vinylimidazole.
Patent NZ-577060-A (NZ)
Title: N- (2-hydroxyethyl) -n-methyl- 4- (quinolin- 8-yl (1- (thiazol-4- ylmethyl) piperidin- 4 -ylidene) methyl) benzamide, the process of making it as well as its use for the treatment of pain, anxiety and depression
Inventor: BUI KHANH
IPC: A61K31/4709
Filed: 2007-10-19
Abstract: Disclosed is a N-(2-hydroxyethyl)-N-methyl-4(quinolin-8-yl(1-(thiazole-4-ylmethyl)piperidin-4-ylidene)methyl)benzamide as shown in formula (I) The compound is a delta agonist useful in the treatment of pain, anxiety or depression.
Patent NZ-579011-A (NZ)
Title: Pleuromutilin derivatives for the treatment of diseases mediated by microbes
Inventor: MANG ROSEMARIE
IPC: A61K31/215
Filed: 2008-03-19
Abstract: Disclosed are pleuromutilin derivatives of formula (I) wherein the substituents are as defined in the specification, and their use in treating diseases mediated by microbes.
Patent NZ-580022-A (NZ)
Title: Integral two layer preform for bag in container with layers releasable from each other by introduction of gas and melting temperature of inner layer not less than outer layer
Inventor: VAN HOVE SARAH
IPC: B32B7/027
Filed: 2008-04-18
Abstract: Disclosed is an integral two-layer preform (1) for the production of integrally blow- moulded bag-in-containers (2). The preform has an inner layer (11) and an outer layer (12), wherein the preform forms a two layer container upon blow-moulding, and wherein the thus obtained inner layer of the container releases from the thus obtained outer layer upon introduction of a gas at a point of interface of the two layers. The melting temperature of the inner layer is greater than or equal to the melting temperature of the outer layer.
Patent NZ-585271-A (NZ)
Title: Process for preparing a fermented beverage comprising addition of a natural source of iso-alpha-acids and a metal oxide such as magnesium oxide to a heated liquid before addition to the wort
Inventor: ADAM PIERRE MARIE FERNAND
IPC: C12C3/12
Filed: 2008-10-29
Abstract: Disclosed is a process for obtaining a minimum concentration of 20 x 10-6 kg/L of iso-alpha-acids in a liquid composition, said process being characterized by mixing in water: a natural source of á-acids and at least one metal oxide, wherein a natural source of á-acids means a non-extracted source of alpha -acids. Also disclosed is a process for preparing a fermented beverage comprising the following steps producing a mash, filtering said mash and recovering the wort, boiling said wort, fermenting said wort to produce a fermented beverage, characterized in that, a liquid composition comprising iso-alpha-acids is added to said wort or to said fermented beverage and in that said liquid composition is prepared in situ prior to its addition to the wort or fermented beverage by mixing in water at least one metal oxide with a natural source of alpha-acids, wherein a natural source of alpha-acids means a non-extracted source of alpha-acids.
Patent NZ-587914-A (NZ)
Title: Controlling production of transportation fuels from renewable feedstocks
Inventor: ANUMAKONDA AMARENDRA
IPC: C10G5/00
Filed: 2009-03-13
Abstract: Disclosed herein is a process for controlling the production of a diesel component comprising hydrocarbons having boiling points in the diesel fuel range and an aviation component comprising hydrocarbons having boiling points in the aviation fuel range from a renewable feedstock, such as plant oils and animal oils, comprising: Determining the required specification of the desired products and the desired relative yields of the product that still meet the required specifications. The necessary isomerisation and selective hydrocracking zone conditions are determined in order to create a mixture of paraffins which meet the required product specifications and yields. A renewable feedstock (2) is treated by hydrogenating and deoxygenating (4) to provide an effluent (6) comprising n-paraffins, isomerising and selectively hydrocracking (22) at least a portion of the n-paraffins at the predetermined conditions to generate branched-paraffins, and separating by fractionation (42) at the predetermined fractionation conditions to generate a diesel range hydrocarbon product (46) and an aviation range hydrocarbon product (45).
Patent NZ-603237-A (NZ)
Title: Tissue scaffolds derived from forestomach extracellular matrix
Inventor: JOHNSON KERYN DALLAS
IPC: A01N1/02
Filed: 2009-07-30
Abstract: NZ 603237 Disclosed is a tissue scaffold comprising the extracellular matrix of the propria-submucosa of the forestomach of a ruminant. Also disclosed is the use of the extracellular matrix of the propria-submucosa of the forestomach of a ruminant in the manufacture of a tissue scaffold for covering a tissue deficits.
Patent NZ-623275-A (NZ)
Title: Treatment of ocular disease
Inventor: PETERS KEVIN
IPC: A61K39/395
Filed: 2012-10-15
Abstract: Disclosed is a use of an ΗΡΤΡβ-ECD binding agent or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the alleviation of an ocular edema.
Patent NZ-624920-A (NZ)
Title: Pharmaceutical compositions and methods of use of 4-pregenen-11ß-17-21-triol-3,20-dione derivatives
Inventor: EDELMAN JEFFREY L
IPC: C07J7/00
Filed: 2012-11-09
Abstract: Provided are ophthalmic compositions of 4-pregenen-11-17-21-triol-3,20-dione derivatives, for example (8S,9S,10R,11S,13S,14S,17R)-17-glycoloyl-11-hydroxy-10,13-dimethyl-3-oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-ylphenylacetate, and their use in the manufacture of a medicament for the treatment of ocular conditions associated with the glucocorticoid receptors (GR) and/or the mineralocorticoid receptors (MR). In a preferred embodiment the ocular condition is ocular rosacea, dry eye, blepharitis or meibomian gland dysfunction.
Patent NZ-630376-A (NZ)
Title: Re-useable injector device for syringe
Inventor: COWE TOBY
IPC: A61M5/31
Filed: 2014-03-07
Abstract: An automatic injection pen with forward housing (110) for holding a syringe and a rearward housing (130) for providing an actuated extension and injection of a needle is described. When the pieces are rotatably connected together (i.e. 165 and 166 are aligned), a switch, latch or other locking member is depressed, allowing the rearward piece to provide the spring loaded injection motion to the plunger of the syringe when a trigger or button (170) is pushed.
Patent NZ-631001-A (NZ)
Title: Solid phase peptide synthesis of insulin using side chain anchored lysine
Inventor: BARLOS KLEOMENIS K
IPC: C07K14/62
Filed: 2013-04-19
Abstract: Disclosed herein is a method for the solid phase synthesis of a protected, partially protected or unprotected peptides including insulin B-chain or an insulin B-chain derivative, wherein the process comprising: preparing a lysine-resin conjugate comprising a resin and a lysine or a lysine derivative of the formula shown herein; and coupling the lysine-resin conjugate of said formula, wherein R is selected from – OH, a carboxyl protecting group and a peptide residue comprising 1 to 200 amino acids comprising optionally protected side chain and optionally protected terminal carboxyl group, with a protected, partially protected or unprotected peptide residue Ib, where the peptide residue comprising 1 to 200 amino acids and the peptide residue Ib together comprises the insulin B-chain or the insulin B-chain derivative, to form the protected, partially protected or unprotected insulin B-chain or an insulin B-chain derivative. The lysine and lysine containing peptides are attached through the lysine side chain on acid and thermo liable resins.
Patent NZ-704266-A (NZ)
Title: Inhibitors of alpha-crystallin aggregation for the treatment for cataract
Inventor: GESTWICKI JASON E
IPC: G01N33/68
Filed: 2013-07-17
Abstract: The invention provides for the use of a compound of formula I, or a pharmaceutically acceptable salt thereof, .in the manufacture of a medicament for the treatment or prevention of cataracts.
Patent NZ-718260-A (NZ)
Title: Energy cable having a crosslinked electrically insulating layer, and method for extracting crosslinking by-products therefrom
Inventor: SICA RODOLFO
IPC: H01B13/24
Filed: 2013-10-23
Abstract: The present invention relates to an electrical power transmission cable comprising at least one cable core comprising an electric conductor formed by a plurality of stranded electrically conducting filaments. The cable core further comprises a crosslinked electrically insulating layer, a semiconducting layer, and zeolite particles placed in the cable core within voids among said filaments, or in contact with the semiconducting layer, or within voids among said filaments and in contact with the semiconducting layer. The zeolite particles are able to extract and absorb, very efficiently and irreversibly, the by-products deriving from the cross-linking reaction, so as to avoid space charge accumulation in the insulating material during cable lifespan. Moreover, the present invention relates to a method for extracting crosslinking by-products from a cross-linked electrically insulating layer of an electrical power transmission cable core, which comprises manufacturing the electrical power transmission cable core comprising an electric conductor, a crosslinked electrically insulating layer containing crosslinking by-products, and zeolite particles. The method further comprises heating the electrical power transmission cable core up to a temperature causing migration of the crosslinking by-products from the crosslinked electrically insulating layer; and then placing a metal screen around the electrical power transmission cable core. The zeolite particles substantially irreversibly absorb some of the crosslinking by-products during the heating step, while a fraction of crosslinking by-products which is gaseous at ambient temperature, such as methane, or which has a low boiling point, is eliminated by causing it to diffuse out of the cable core.
Patent NZ-721355-A (NZ)
Title: Space potential generation device, a storage device for maintaining a freshness of an object stored therein using such space potential generation device, and fryer provided with such space potential generation device
Inventor: GOTO KANETAKA
IPC: F25D11/00
Filed: 2014-11-18
Abstract: The present invention provides a space potential generation device and a storage device for maintaining a freshness of an object stored therein using the space potential generation device enabling to downsize the device as a whole, keep a capacity of the refrigerator same as before the space potential generation device is installed, and generate an electric field in a wide range. In addition, the present invention provides a fryer that efficiently forms an electric field in an oil tub to prevent deterioration of oil and generation of acrylamide, shorten time required for frying, and reduce fat and oil smoke. This space potential generation device is characterized by: being provided with a transformer formed by magnetically joining a primary coil and a secondary coil, a feedback control circuit for returning one terminal of the secondary coil to one terminal of the primary coil to adjust voltage in the secondary coil, an output control means provided on the other terminal of the secondary coil to apply a voltage with low-frequency vibration having a range of 40 to 60 Hz to the output of the secondary coil, the output control portion being a part of the space potential generation device; and a static electricity discharge means disposed on the other terminal of the secondary coil via the output control means and made of a conductive material; and being configured so that there is no ground electrode, the current flowing to the secondary coil is a weak current in the range 0.2-0.002 A, the static electricity discharge means is covered by an insulating member with insulative properties to a degree that allows the discharge of static electricity of a prescribed voltage into a surrounding space, and an electrical field of a prescribed voltage is formed in the space surrounding the static electricity discharge means by the static electricity discharged from the static electricity discharge means.
Patent NZ-744338-A (NZ)
Title: Formulations and methods for controlling the reproductive cycle and ovulation
Inventor: SAMMARTINO DANIEL
IPC: A61K38/24
Filed: 2016-12-16
Abstract: The present invention relates to an injectable formulation comprising progesterone, progestin or analogues thereof, wherein a portion of said hormone is dissolved in an organic solvent to form a free portion and a portion of said hormone is enclosed by fatty acids to form an enclosed portion and wherein both portions are included in a gel matrix. This formulation allows a controlled release profile of progesterone to promote ovulation or synchronizing the ovulation or heat/estrus of a group of female mammals more effectively than intra-vaginal devices commonly used in the art. In general, hormone formulations, dosage units including the hormone formulations, and methods of use relate to a controlled release formulation, which includes hormones, e.g., progesterone are described. Formulations and methods are for controlling the reproductive cycle and/or ovulation of a female mammal, for example, to promote ovulation in a female mammal or synchronizing the ovulation or heat/estrus of a group of female mammals. In addition, formulations are for increasing the likelihood that a female mammal becomes pregnant, for example, after insemination or embryo transference. In addition, formulations are for reducing the anestrous period in a female mammal.
Patent NZ-748590-A (NZ)
Title: Drive system for high-voltage electrical devices
Inventor: SABAS FERNANDEZ JOSÉ LUIS
IPC: H01H33/42
Filed: 2018-11-20
Abstract: The present invention relates to a drive system (1) for high-voltage electrical devices (3, 4), such as a load break switch-disconnector (3) and a grounding disconnector (4), which can be applied in utility grids, allowing said drive system (1) to motorize the switching of both electrical devices (3, 4). To that end, the drive system (1) comprises a subassembly (2) which allows selecting the motorized switching operation of the first electrical device (3) or the motorized switching operation of the second electrical device (4). The motorization of the switching of both electrical devices (3, 4) thereby allows performing said operation remotely.
Patent NZ-749031-A (NZ)
Title: Integrin receptor antagonists and their methods of use
Inventor: MACKEL MICHAEL
IPC: A61P35/00
Filed: 2012-05-09
Abstract: Disclosed is a method for inhibiting alpha3Beta1-lntegrin, alpha5beta1-lntegrin, alphavbeta3-lntegrin and alphavbeta5-lntegrin, and/or other integrins and/or for inhibiting bFGF production in a human or animal subject, said method comprising the step of: administering to the subject an effective amount of an RG Cysteic Acid Peptide or derivative thereof.
Patent NZ-753803-A (NZ)
Title: Delivery of respiratory therapy
Inventor: VELISS LEE JAMES
IPC: A61M16/00
Filed: 2007-07-27
Abstract: A patient interface for delivering pressurized breathable gas to a patient for treatment of sleep disordered breathing, including: a frame (integral with tubes 351); a base portion (350) provided to the frame, the frame being more rigid than the base portion; and a sealing portion (352) attached to the base portion and adapted to sealingly engage the patient’s face. The sealing portion comprises textile has an opening formed therein to deliver pressurized breathable gas to the patient’s airways in use.
Patent NZ-757587-A (NZ)
Title: Molten metal stirring device and continuous casting device system provided with same
Inventor: TAKAHASHI KENZO
IPC: B22D11/115
Filed: 2018-04-11
Abstract: [Problem] In continuous casting, to provide a product having excellent quality with high productivity. [Solution] Molten metal from a melting furnace is agitated and driven by means of a Lorentz force resulting from an intersection of a line of magnetic force from a magnet and a direct current, and is fed to a mold while the quality of the molten metal is improved, or the molten metal immediately before solidification in the mold is agitated and driven by said Lorentz force to homogenize the temperature of the molten metal immediately before solidification in the mold, thereby ultimately obtaining a high-quality product and providing a means for cooling the magnet and maintaining the performance of the magnet.